Cambodia today granted an Emergency Use Authorisation (EUA) licence for India-made COVAXIN vaccine against COVID-19.
The vaccine is for active immunisation of individual of 18 years old and up for the prevention of coronavirus disease 2019 (COVID-19), according to the COVAXIN’s description.
COVAXIN is manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).
The World Health Organisation (WHO) issued emergency use listing (EUL) for COVAXIN on Nov. 3, 2021.
Cambodia has so far issued EUA for China-manufactured Sinopharm and Sinovac vaccines, the AstraZeneca developed by the University of Oxford, and Russia-made Sputnik V, CoviVac, Sputnik-Light, and EpiVacCorona.
As of Nov. 4, 86.87 percent of Cambodia’s total population of 16 million have been vaccinated against the COVID-19 pandemic.
